Domino's Pizza is trading at roughly 20 times earnings, more than a third below its typical valuation over the past decade. The stock's cheapness reflects investor fears that GLP-1 weight loss drugs and sluggish traffic could structurally break the chain's growth story. U.S. same-store sales rose just 0.9% in Q1 and 0.1% in Q2, while international comps turned slightly negative excluding foreign exchange. Analysts expect tens of millions of Americans to be on drugs like Wegovy and Zepbound by 2030, with studies showing real drops in calorie intake and restaurant data suggesting GLP-1 users eat out less. Domino's CEO says the chain has not yet seen a measurable GLP-1 impact, but markets are pricing in the possibility that late-night pizza demand shrinks.
Domino's Pizza Inc Common StockArticle discusses fears that GLP-1 drugs and sluggish traffic could hurt pizza demand, with weak same-store sales.
Domino’s Pizza Group PLC
NVIDIA Corporation